Jeffrey W. Albers net worth and biography

Jeffrey Albers Biography and Net Worth

Director of Spyre Therapeutics

Jeffrey W. Albers has over 25 years of experience working in the biopharmaceutical industry and bringing important new medicines to patients with cancer and rare diseases. He is currently Chairman of Blueprint Medicines Corporation (Nasdaq: BPMC), a global precision therapy company, since January 2023, and Venture Partner at Atlas Venture, a venture capital firm focused on investment in biotechnology companies, since January 2023. Mr. Albers served as Chief Executive Officer, President and Chairman of Blueprint Medicines from June 2021 to April 2022, Executive Chairman from April 2022 to December 2022 and as Chief Executive Officer, President and Director from July 2014 to June 2021. Prior to joining Blueprint Medicines in July 2014, Mr. Albers was President of Algeta ASA, a Norwegian biotechnology company from January 2012 to April 2014, where he oversaw the commercial and business functions. Prior to Algeta ASA, from July 2005 to November 2011, Mr. Albers was at Genzyme Corporation, a biotechnology company that is now a wholly-owned subsidiary of Sanofi S.A., most recently as Vice President of the U.S. hematology and oncology business unit. In addition to Blueprint Medicines, Mr. Albers serves on the board of directors of Kymera Therapeutics, Inc. (Nasdaq: KYMR) and several private companies. Mr. Albers received a B.S. from Indiana University and an M.B.A. and a J.D. from Georgetown University.

What is Jeffrey W. Albers' net worth?: The estimated net worth of Jeffrey W. Albers is at least $1.82 million as of January 21st, 2025. Mr. Albers owns 152,396 shares of Spyre Therapeutics stock worth more than $1,818,084 as of April 11th. This net worth evaluation does not reflect any other assets that Mr. Albers may own. Learn More about Jeffrey W. Albers' net worth.
How do I contact Jeffrey W. Albers?: The corporate mailing address for Mr. Albers and other Spyre Therapeutics executives is 805 Las Cimas Parkway, Suite 100, Austin, TX 78746, United States. Spyre Therapeutics can also be reached via phone at 512-942-2935 and via email at investors@aeglea.com. Learn More on Jeffrey W. Albers' contact information.
Has Jeffrey W. Albers been buying or selling shares of Spyre Therapeutics?: Jeffrey W. Albers has not been actively trading shares of Spyre Therapeutics during the last ninety days. Most recently, Jeffrey W. Albers sold 300 shares of the business's stock in a transaction on Friday, October 25th. The shares were sold at an average price of $36.43, for a transaction totalling $10,929.00. Following the completion of the sale, the director now directly owns 34,060 shares of the company's stock, valued at $1,240,805.80. Learn More on Jeffrey W. Albers' trading history.
Are insiders buying or selling shares of Spyre Therapeutics?: In the last twelve months, insiders at the sold shares 1 times. They sold a total of 300 shares worth more than $10,929.00. The most recent insider tranaction occured on October, 25th when Director Jeffrey W Albers sold 300 shares worth more than $10,929.00. Insiders at Spyre Therapeutics own 6.2% of the company. Learn More about insider trades at Spyre Therapeutics.
Information on this page was last updated on 10/25/2024.

Jeffrey W. Albers Insider Trading History at Spyre Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
10/25/2024	Sell	300	$36.43	$10,929.00	34,060

Jeffrey W. Albers Buying and Selling Activity at Spyre Therapeutics

Spyre Therapeutics Company Overview

Spyre Therapeutics, Inc., a preclinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD). It develops SPY001, a human monoclonal immunoglobulin G1 antibody designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's disease). The company is also developing SPY002, a human monoclonal antibody (mAb)candidates designed to bind to tumor necrosis factor-like ligand 1A; and SPY120, a combination of SPY001 (anti-a4ß7) and SPY002 (anti-TL1A) antibodies, which are in preclinical studies. In addition, its other early-stage programs include SPY003, an anti-IL-23 mAb; SPY004, a novel mechanism of action (MOA) mAb; SPY130, a combination of anti-a4ß7 and anti-IL-23 mAbs; and SPY230, a combination of anti-TL1A and anti-IL-23 mAbs. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was incorporated in 2013 and is based in Waltham, Massachusetts.

Today's Range

Now: $11.93

$11.62

$12.95

50 Day Range

MA: $18.69

$11.80

$23.86

2 Week Range

Now: $11.93

$10.91

$40.84

Volume

978,765 shs

Average Volume

582,882 shs

Market Capitalization

$718.87 million

P/E Ratio

N/A

Dividend Yield